These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 21394747)

  • 1. A method to estimate treatment efficacy among latent subgroups of a randomized clinical trial.
    Altstein LL; Li G; Elashoff RM
    Stat Med; 2011 Mar; 30(7):709-17. PubMed ID: 21394747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Latent subgroup analysis of a randomized clinical trial through a semiparametric accelerated failure time mixture model.
    Altstein L; Li G
    Biometrics; 2013 Mar; 69(1):52-61. PubMed ID: 23383608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of statistical methods for analysing survival data in the presence of non-random compliance.
    Odondi L; McNamee R
    Stat Med; 2010 Dec; 29(29):2994-3003. PubMed ID: 20963732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment evaluation for a data-driven subgroup in adaptive enrichment designs of clinical trials.
    Zhang Z; Chen R; Soon G; Zhang H
    Stat Med; 2018 Jan; 37(1):1-11. PubMed ID: 28948633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A nonparametric method for value function guided subgroup identification via gradient tree boosting for censored survival data.
    Zhang P; Ma J; Chen X; Shentu Y
    Stat Med; 2020 Dec; 39(28):4133-4146. PubMed ID: 32786155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimating treatment effect in a proportional hazards model in randomized clinical trials with all-or-nothing compliance.
    Li S; Gray RJ
    Biometrics; 2016 Sep; 72(3):742-50. PubMed ID: 26799700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using the instrumental variables estimator to analyze noninferiority trials with noncompliance.
    Kim MY
    J Biopharm Stat; 2010 Jul; 20(4):745-58. PubMed ID: 20496203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subgroups from regression trees with adjustment for prognostic effects and postselection inference.
    Loh WY; Man M; Wang S
    Stat Med; 2019 Feb; 38(4):545-557. PubMed ID: 29671896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A structural mean model to allow for noncompliance in a randomized trial comparing 2 active treatments.
    Fischer K; Goetghebeur E; Vrijens B; White IR
    Biostatistics; 2011 Apr; 12(2):247-57. PubMed ID: 20805286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stochastic EM algorithm for doubly interval-censored data.
    Dejardin D; Lesaffre E
    Biostatistics; 2013 Sep; 14(4):766-78. PubMed ID: 23728851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Likelihood methods for treatment noncompliance and subsequent nonresponse in randomized trials.
    O'Malley AJ; Normand SL
    Biometrics; 2005 Jun; 61(2):325-34. PubMed ID: 16011678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of statistical issues with progression-free survival as an interval-censored time-to-event endpoint.
    Sun X; Li X; Chen C; Song Y
    J Biopharm Stat; 2013; 23(5):986-1003. PubMed ID: 23957511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and semiparametric analysis of non-inferiority trials with active and placebo control for censored time-to-event data.
    Kombrink K; Munk A; Friede T
    Stat Med; 2013 Aug; 32(18):3055-66. PubMed ID: 23508697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quint: An R package for the identification of subgroups of clients who differ in which treatment alternative is best for them.
    Dusseldorp E; Doove L; Mechelen Iv
    Behav Res Methods; 2016 Jun; 48(2):650-63. PubMed ID: 26092391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should baseline be a covariate or dependent variable in analyses of change from baseline in clinical trials?
    Liu GF; Lu K; Mogg R; Mallick M; Mehrotra DV
    Stat Med; 2009 Sep; 28(20):2509-30. PubMed ID: 19610129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subgroup identification in dose-finding trials via model-based recursive partitioning.
    Thomas M; Bornkamp B; Seibold H
    Stat Med; 2018 May; 37(10):1608-1624. PubMed ID: 29388228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonparametric inference for assessing treatment efficacy in randomized clinical trials with a time-to-event outcome and all-or-none compliance.
    Elashoff RM; Li G; Zhou Y
    Biometrika; 2012 Jun; 99(2):393-404. PubMed ID: 23843664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An efficient algorithm to determine the optimal two-stage randomized multinomial designs in oncology clinical trials.
    Zhang Y; Mietlowski W; Chen B; Wang Y
    J Biopharm Stat; 2011 Jan; 21(1):56-65. PubMed ID: 21191854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial.
    Wedel H; Demets D; Deedwania P; Fagerberg B; Goldstein S; Gottlieb S; Hjalmarson A; Kjekshus J; Waagstein F; Wikstrand J;
    Am Heart J; 2001 Sep; 142(3):502-11. PubMed ID: 11526365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials.
    Pond GR; Abbasi S
    Clin Trials; 2011 Jun; 8(3):260-9. PubMed ID: 21511687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.